Immuneering Corporation (IMRX), a clinical-stage oncology company, Thursday said it has signed a clinical supply agreement with ...

Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase ...

(Reuters) - Regeneron (NASDAQ: REGN) Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing ...